5 EASY FACTS ABOUT ABBV-744 BRD4 INHIBITOR MECHANISM OF ACTION DESCRIBED

In Phase C, participants will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.Attainable new ways for your diagnosis and treatment of AML. (A) The identification of Tremendous